Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexza Pharmaceuticals has initiated a phase IIa clinical trial with its inhalation product candidate AZ-002 to treat episodes of acute panic disorder in 36 patients.
Subscribe to our email newsletter
The primary aim of the clinical trial is to assess the safety and efficacy of a single dose of AZ-002 in treating a pharmacologically-induced panic attack. Changes in the intensity and the duration of a panic attack using psychological and physiological measurements will be evaluated at multiple time points during the study.
According to the company, the physical and emotional symptoms of a panic attack have many variations, but often begin rapidly, peak within 10 minutes and last about 30 minutes.
There are currently no drugs approved for the acute treatment of panic attacks. Oral formulations of drugs like alprazolam are approved for chronic use to treat panic disorder. These drugs are intended to reduce the frequency of panic attacks, but they do not typically eliminate their occurrence.